Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide for Type II Odontoid Fractures in Older Adults
NCT04760782Phase 2Terminated
- Start
- May 2022
- Primary completion
- Aug 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of abaloparatide in odontoid fracture (2 arms). Primary endpoint: Fracture Union at 3 months. Started May 2022; status: terminated.
02
Drugs
abaloparatide
03
Conditions
odontoid fracture
Beyond the preview
Go deeper on NCT04760782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04760782.